secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000950170-23-042419
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q2 net loss $80.2M; winds down tarcocimab after Phase 3 DME miss
--------------------------------------------------------------------------------

- Q2 2023 net loss $80.2M ($1.53/sh) vs $90.6M ($1.74/sh) in Q2 2022.
- Cash and equivalents $378.7M at June 30, 2023.
- Phase 3 GLEAM and GLIMMER in DME missed primary efficacy endpoint; tarcocimab studies being wound down.
- Phase 3 DAYLIGHT in wet AMD met endpoint; no cataract imbalance observed.
- KSI-501 Phase 1 enrollment completed; exploring both unconjugated protein and bioconjugate forms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023042419/0000950170-23-042419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017023042419/kod-20230814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer